These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23059401)

  • 1. Everolimus improves experimental autoimmune uveoretinitis.
    Hennig M; Bauer D; Wasmuth S; Busch M; Walscheid K; Thanos S; Heiligenhaus A
    Exp Eye Res; 2012 Dec; 105():43-52. PubMed ID: 23059401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of systemic and intravitreal TNF-α inhibition in experimental autoimmune uveoretinitis.
    Busch M; Bauer D; Hennig M; Wasmuth S; Thanos S; Heiligenhaus A
    Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):39-46. PubMed ID: 23211816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
    Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
    Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
    Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of experimental autoimmune uveitis in mice treated with FTY720.
    Commodaro AG; Peron JP; Lopes CT; Arslanian C; Belfort R; Rizzo LV; Bueno V
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2568-74. PubMed ID: 20019358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.
    Martín AP; de Moraes LV; Tadokoro CE; Commodaro AG; Urrets-Zavalia E; Rabinovich GA; Urrets-Zavalia J; Rizzo LV; Serra HM
    Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2056-63. PubMed ID: 15914623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor.
    Zhang L; Ma J; Takeuchi M; Usui Y; Hattori T; Okunuki Y; Yamakawa N; Kezuka T; Kuroda M; Goto H
    Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2109-17. PubMed ID: 20007828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity.
    Zhang X; Ren X; Li G; Jiao C; Zhang L; Zhao S; Wang J; Han ZC; Li X
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3143-52. PubMed ID: 21296818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
    Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
    Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU).
    Kasper M; Gabriel D; Möller M; Bauer D; Wildschütz L; Courthion H; Böhm MRR; Busch M; Loser K; Thanos S; Gurny R; Heiligenhaus A
    Exp Eye Res; 2018 Mar; 168():49-56. PubMed ID: 29326066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
    Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
    Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of intravitreal administration of tresperimus, an immunosuppressive drug, on experimental autoimmune uveoretinitis.
    Bousquet E; Camelo S; Leroux les Jardins G; Goldenberg B; Naud MC; Besson-Lescure B; Lebreton L; Annat J; Behar-Cohen F; de Kozak Y
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5414-23. PubMed ID: 21666239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody.
    Zhang R; Qian J; Guo J; Yuan YF; Xue K
    Curr Eye Res; 2009 Apr; 34(4):297-303. PubMed ID: 19373578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of experimental autoimmune uveoretinitis induced by interphotoreceptor retinoid-binding protein.
    Kawashima H; Fujiño Y; Mochizuki M
    Jpn J Ophthalmol; 1991; 35(1):51-60. PubMed ID: 1895569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.
    Guyver CJ; Copland DA; Calder CJ; Sette A; Sidney J; Dick AD; Nicholson LB
    Invest Ophthalmol Vis Sci; 2006 May; 47(5):2027-35. PubMed ID: 16639012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
    Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
    Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.
    Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.